pf-07054894
Small moleculeexperimental
Clinical trial activity
4 trials · 1 clinical orgs · 0 marketing orgs
Phase 1
4
Phase 2
0
Phase 3
0
Phase 4
0
Earliest trial started Jun 11, 2020 (NCT04388878)
Timeline
2020s
- Jan 1, 2020
Earliest Phase 1 Sponsor(trial)
Indications
Mechanism of action
- C-C chemokine receptor type 6ANTAGONIST
CCR6 antagonist
Chemistry & pharmacology
Loading structure…
SMILES
Cc1cn(C)nc1[C@H](Nc1c(Nc2ccnc(C(=O)N(C)C)c2O)c(=O)c1=O)C1(C)CCCC1- Mol. weight
- 466.54 g/mol
- Lipinski Ro5
- Pass
- Rule of 3
- No
- Chirality
- Single Stereoisomer
- Inorganic
- No
- Polymer
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL6068520 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT07009353 | Phase 1 | Jun 20, 2025 | Pfizer |
| NCT06327880 | Phase 1 | May 13, 2024 | Pfizer |
| NCT05549323 | Phase 1 | Nov 7, 2022 | Pfizer |
| NCT04388878 | Phase 1 | Jun 11, 2020 | Pfizer |
Showing 4 of 4 trials
Page 1 / 1
Organizations
Research & Development (1)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Pfizer | For profit | 4 | 4 | 1 | 2020 |
1 organizations
Page 1 / 1